| Predicate |
Object |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4035
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D217-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D209-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-472
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D217-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4035
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-472
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P21-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D209-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D209-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 |
| filingDate |
2000-05-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2003-02-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2003504307-A |
| titleOfInvention |
Cyclic amidines useful as NMDANR2B antagonists |
| abstract |
SUMMARY OF THE INVENTION The present invention provides a novel compound of formula I and a non-toxic dose of a compound of formula I effective to block the NMDA NR2B receptor subunit in patients having a need to treat NMDA-mediated diseases. And a method of treating an NMDA-mediated disease comprising administering. The invention also includes certain pharmaceutical compositions for treating NMDA-mediated diseases comprising a compound of Formula I and a pharmaceutically acceptable carrier. Embedded image |
| priorityDate |
1999-05-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |